The stock of Prothena Corporation PLC (NASDAQ:PRTA) is a huge mover today! About 265,146 shares traded hands. Prothena Corporation PLC (NASDAQ:PRTA) has risen 80.57% since March 8, 2016 and is uptrending. It has outperformed by 71.25% the S&P500.
The move comes after 5 months negative chart setup for the $2.08 billion company. It was reported on Oct, 11 by Barchart.com. We have $53.54 PT which if reached, will make NASDAQ:PRTA worth $187.20 million less.
Analysts await Prothena Corporation PLC (NASDAQ:PRTA) to report earnings on November, 7. They expect $-1.23 earnings per share, down 68.49% or $0.50 from last year’s $-0.73 per share. After $-1.18 actual earnings per share reported by Prothena Corporation PLC for the previous quarter, Wall Street now forecasts 4.24% negative EPS growth.
Prothena Corporation PLC (NASDAQ:PRTA) Ratings Coverage
Out of 4 analysts covering Prothena Corp (NASDAQ:PRTA), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Prothena Corp has been the topic of 9 analyst reports since July 22, 2015 according to StockzIntelligence Inc. On Thursday, August 4 the stock rating was maintained by Barclays Capital with “Overweight”. The rating was maintained by Wedbush on Tuesday, August 4 with “Outperform”. The stock of Prothena Corporation PLC (NASDAQ:PRTA) has “Outperform” rating given on Friday, February 19 by Wedbush. The rating was initiated by Credit Suisse on Thursday, January 21 with “Outperform”. Barclays Capital initiated it with “Overweight” rating and $60 target price in Friday, May 13 report. On Thursday, November 19 the stock rating was maintained by RBC Capital Markets with “Outperform”.
According to Zacks Investment Research, “Prothena Corporation plc is a biotechnology company focused on the discovery and development of therapeutic monoclonal antibodies for disease-causing proteins. The Company is developing the following programs: NEOD001 for Amyloidosis, NEOD002 for Parkinson’s disease, MCAM for Inflammatory disease and Metastatic Cancer and Tau for Alzheimer’s disease. Prothena Corporation plc is headquartered in Dublin, Ireland.”
Insitutional Activity: The institutional sentiment decreased to 1.04 in Q2 2016. Its down 0.23, from 1.27 in 2016Q1. The ratio fall, as 13 funds sold all Prothena Corporation PLC shares owned while 40 reduced positions. 11 funds bought stakes while 44 increased positions. They now own 23.97 million shares or 13.54% less from 27.72 million shares in 2016Q1.
Bank & Trust Of Montreal Can has invested 0% of its portfolio in Prothena Corporation PLC (NASDAQ:PRTA). Thrivent Fin For Lutherans holds 0.01% of its portfolio in Prothena Corporation PLC (NASDAQ:PRTA) for 32,100 shares. The California-based Wells Fargo & Mn has invested 0.01% in Prothena Corporation PLC (NASDAQ:PRTA). The Pennsylvania-based Nationwide Fund Advsrs has invested 0.01% in Prothena Corporation PLC (NASDAQ:PRTA). Mycio Wealth Limited Liability Corp holds 289 shares or 0% of its portfolio. Camarda Advsrs Ltd Liability owns 12 shares or 0% of their US portfolio. Us Retail Bank De last reported 0% of its portfolio in the stock. Tradewinds Cap Mngmt Lc holds 0% of its portfolio in Prothena Corporation PLC (NASDAQ:PRTA) for 7 shares. Whittier Co Of Nevada Incorporated has invested 0% of its portfolio in Prothena Corporation PLC (NASDAQ:PRTA). American Intll Grp Incorporated, a New York-based fund reported 19,995 shares. Checchi Advisers Ltd Llc has 12,995 shares for 0.05% of their US portfolio. Mariner Investment Grp holds 0.39% or 33,104 shares in its portfolio. Royal National Bank Of Canada has invested 0% of its portfolio in Prothena Corporation PLC (NASDAQ:PRTA). Blackrock Japan Co Ltd holds 0% of its portfolio in Prothena Corporation PLC (NASDAQ:PRTA) for 220 shares. Allianz Asset Management Ag accumulated 0% or 31,398 shares.
Insider Transactions: Since April 13, 2016, the stock had 0 insider purchases, and 5 insider sales for $1.88 million net activity. The insider HOMAN ARTHUR W sold 3,125 shares worth $162,991. The insider Selkoe Dennis J. sold $225,000. Walker Karin L sold $180,449 worth of stock.
More notable recent Prothena Corporation PLC (NASDAQ:PRTA) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on April 02, 2013, also Fool.com with their article: “Why Prothena Corporation Plc is Soaring Higher Today” published on March 20, 2015, Twst.com published: “Prothena Corporation plc: Prothena Announces Appointment of Dr. Gene G. Kinney …” on October 03, 2016. More interesting news about Prothena Corporation PLC (NASDAQ:PRTA) were released by: Twst.com and their article: “Prothena Corporation plc: Prothena to Host Update on PRX003 Phase 2 …” published on September 22, 2016 as well as Streetinsider.com‘s news article titled: “Form 8-K Prothena Corp plc For: Sep 26” with publication date: September 26, 2016.
PRTA Company Profile
Prothena Corporation Public Limited Company, incorporated on September 26, 2012, is a global biotechnology company. The Firm is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003). The Firm has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company’s pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.